U.S., May 17 -- ClinicalTrials.gov registry received information related to the study (NCT06975748) titled 'A Phase II Study of STSP-0902 Ophthalmic Solution in Patients With Neurotrophic Keratitis' on April 15.
Brief Summary: This is a Phase II, double-blind, placebo-controlled study to evaluate the safety and efficacy of STSP-0902 ophthalmic solution in patients with neurotrophic keratitis (NK). The study plans to enroll 48 patients with Mackie Stage 2 or 3 NK affecting one or both eyes. Eligible subjects will be randomized 1:1:1 into three dosing groups. Each dosing group will follow a drug-placebo allocation (12 active: 4 placebo). Treatment involves topical ocular administration for 8 weeks. Subjects who are not healed after the 8 wee...